Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(7):542-543; doi:10.1093/jnci/dji091
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Martino, S.
Right arrow Articles by Cummings, S. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Martino, S.
Right arrow Articles by Cummings, S. R.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

CORRESPONDENCE

RESPONSE: Re: Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene

Silvana Martino, Jane A. Cauley, Elizabeth Barrett-Connor, Trevor J. Powles, John Mershon, Damon Disch, Roberta J. Secrest, Steven R. Cummings

Affiliations of authors: Cancer Institute Medical Group, Santa Monica, CA (SM); University of Pittsburgh, Pittsburgh, PA (JAC); University of California, San Diego, La Jolla, CA (EBC); Institute of Cancer Research, Parkside Oncology Clinic, London, United Kingdom (TJP); Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN (JM, DD, RJS); San Francisco Coordinating Center, California Pacific Medical Center Research Institute and the Department of Epidemiology and Biostatistics at the University of California, San Francisco, CA (SRC)

Correspondence to: Silvana Martino, DO, Cancer Institute Medical Group, 2001 Santa Monica Blvd., Ste. 560W, Santa Monica, CA 90404 (e-mail: smartino@cimg.org).

The first 10% of the full text of this article appears below.

The comments from Dr. Yalcin and colleagues raise a clinically relevant question. Clinical data suggest that the use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), including cyclooxygenase-2 (COX-2) inhibitors, is associated with decreased risks of several cancers, including breast cancer (. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

Re: Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene
Bulent Yalcin, Abdullah Buyukcelik, Samet Yalcin, Gungor Utkan, Hatice Doruk, Mutlu Dogan, and Mehmet Altan
J Natl Cancer Inst 2005 97: 542. [Extract] [Full Text] [PDF]